- Home
- TEI vs AMRN Comparison
TEI vs AMRN Comparison
Compare TEI & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEI
- AMRN
- Stock Information
- Founded
- TEI 1993
- AMRN 1989
- Country
- TEI United States
- AMRN Ireland
- Employees
- TEI N/A
- AMRN 275
- Industry
- TEI Finance Companies
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- TEI Finance
- AMRN Health Care
- Exchange
- TEI Nasdaq
- AMRN Nasdaq
- Market Cap
- TEI 262.1M
- AMRN 189.2M
- IPO Year
- TEI N/A
- AMRN 1993
- Fundamental
- Price
- TEI $5.20
- AMRN $0.46
- Analyst Decision
- TEI
- AMRN Buy
- Analyst Count
- TEI 0
- AMRN 1
- Target Price
- TEI N/A
- AMRN N/A
- AVG Volume (30 Days)
- TEI 142.4K
- AMRN 1.7M
- Earning Date
- TEI 01-01-0001
- AMRN 10-30-2024
- Dividend Yield
- TEI 10.51%
- AMRN N/A
- EPS Growth
- TEI N/A
- AMRN N/A
- EPS
- TEI N/A
- AMRN N/A
- Revenue
- TEI N/A
- AMRN $241,021,000.00
- Revenue This Year
- TEI N/A
- AMRN N/A
- Revenue Next Year
- TEI N/A
- AMRN N/A
- P/E Ratio
- TEI N/A
- AMRN N/A
- Revenue Growth
- TEI N/A
- AMRN N/A
- 52 Week Low
- TEI $4.35
- AMRN $0.43
- 52 Week High
- TEI $5.39
- AMRN $1.37
- Technical
- Relative Strength Index (RSI)
- TEI 37.23
- AMRN 40.30
- Support Level
- TEI $5.10
- AMRN $0.43
- Resistance Level
- TEI $5.27
- AMRN $0.50
- Average True Range (ATR)
- TEI 0.07
- AMRN 0.03
- MACD
- TEI -0.02
- AMRN 0.00
- Stochastic Oscillator
- TEI 31.43
- AMRN 30.00
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments and Money Market Funds.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.